Publication:
Evaluation of renal effects of dapagliflozin in diabetic rats with subacute exposure

Simple item page
dc.contributor.authorERCAN, FERİHA
dc.contributor.authorsBORAN T., Ulus Karaca B., Karagöz Köroğlu A., ERCAN F., ÖZHAN G.
dc.date.accessioned2023-09-18T10:55:06Z
dc.date.available2023-09-18T10:55:06Z
dc.date.issued2023-09-01
dc.description.abstractDapagliflozin (DAPA), a sodium glucose co-transporter 2 (SGLT2) inhibitor, is used for the treatment of type 2 diabetes. Although several studies have demon-strated its protective effects on the kidney, the FDA warns about the risk of DA-PA-induced nephrotoxicity. SGLT2 inhibitors may induce oxidative stress and inflammation in the kidney due to their mechanism of action. In the present study, it was aimed to clarify the molecular effects of DAPA on the kidney. Diabetes was induced by single injection of streptozotocin (STZ) (35 mg/kg b.w.) after the rats were fed with high-fat diet for two-weeks. Diabetic rats were administered with DAPA at 10 mg/kg by oral gavage for 28 days. The oxidative stress, inflammation and apoptosis induction potentials of DAPA were evaluated. The morpholog-ical changes and apoptosis were investigated by histological examinations. The findings showed that DAPA treatment reduced oxidative parameters and slightly inhibited inflammatory mediator levels. According to the histological examinations, DAPA ameliorated the diabetes-induced changes and apoptosis. As a result, DAPA showed a protective effect on the kidney by alleviating oxidative stress and inhibiting inflammation and apoptosis. However, further studies are needed to determine the long-term effects of DAPA on the kidney in diabetic patients.
dc.identifier.citationBORAN T., Ulus Karaca B., Karagöz Köroğlu A., ERCAN F., ÖZHAN G., "Evaluation of Renal Effects of Dapagliflozin in Diabetic Rats With Subacute Exposure", Hacettepe University Journal of the Faculty of Pharmacy, cilt.43, sa.3, ss.232-242, 2023
dc.identifier.doi10.52794/hujpharm.1171489
dc.identifier.endpage242
dc.identifier.issn1300-0608
dc.identifier.issue3
dc.identifier.startpage232
dc.identifier.urihttps://avesis.marmara.edu.tr/api/publication/d9625591-823a-4eb2-96e0-3ffd9bfd416c/file
dc.identifier.urihttps://hdl.handle.net/11424/293488
dc.identifier.volume43
dc.language.isoeng
dc.relation.ispartofHacettepe University Journal of the Faculty of Pharmacy
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectTemel Eczacılık Bilimleri
dc.subjectEczacılık
dc.subjectYaşam Bilimleri
dc.subjectSağlık Bilimleri
dc.subjectTemel Bilimler
dc.subjectBasic Pharmaceutics Sciences
dc.subjectPharmacology and Therapeutics
dc.subjectLife Sciences
dc.subjectHealth Sciences
dc.subjectNatural Sciences
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectFarmakoloji ve Toksikoloji
dc.subjectFARMAKOLOJİ VE ECZACILIK
dc.subjectLife Sciences (LIFE)
dc.subjectPHARMACOLOGY & TOXICOLOGY
dc.subjectPHARMACOLOGY & PHARMACY
dc.subjectGenel Farmakoloji, Toksikoloji ve Eczacılık
dc.subjectGeneral Pharmacology, Toxicology and Pharmaceutics
dc.subjectDapagliflozin
dc.subjectdiabetes
dc.subjectnephrotoxicity
dc.subjectrenoprotective effect
dc.subjectSGLT2 inhibitors
dc.subjectDapagliflozin
dc.subjectSGLT2 inhibitors
dc.subjectnephrotoxicity
dc.subjectdiabetes
dc.subjectrenoprotective effect
dc.titleEvaluation of renal effects of dapagliflozin in diabetic rats with subacute exposure
dc.typearticle
dspace.entity.typePublication
local.avesis.idd9625591-823a-4eb2-96e0-3ffd9bfd416c
local.indexed.atSCOPUS
relation.isAuthorOfPublicationadc800ed-105c-40c7-a572-6cf3f175be92
relation.isAuthorOfPublication.latestForDiscoveryadc800ed-105c-40c7-a572-6cf3f175be92

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
3.pdf
Size:
1.3 MB
Format:
Adobe Portable Document Format
Download

Collections

Research Outputs